Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma [0.03%]
纳武单抗联合苯达莫司汀和利妥昔单抗治疗初治复发/难治弥漫性大B细胞淋巴瘤患者：2期研究结果
Nathalie A Johnson,Pier Luigi Zinzani,Eva Domingo-Domenech et al.
Nathalie A Johnson et al.
Aims: Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) have relapsed or refractory (R/R) disease after first-line treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, a...
Outcomes of people living with acute lymphoblastic leukemia who received inotuzumab ozogamicin before a stem cell transplant: a plain language summary [0.03%]
关于接受英法妥单抗治疗并在造血干细胞移植前被诊断为急性淋巴细胞白血病患者的结局：易懂版
Marcos de Lima,Partow Kebriaei,Francesco Lanza et al.
Marcos de Lima et al.
Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US [0.03%]
美国非驱动基因转移性非小细胞肺癌的治疗模式和减员状况分析
Adam J Schoenfeld,Chen Hu,Ravi Rajaram et al.
Adam J Schoenfeld et al.
Aims: Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) inhibitors (PD-[L]1) are standard of care for patients with metastatic non-small cell lung cancer (mNSCLC). This study examined real-world treatment patterns and...
Real-world treatment and utilization of venetoclax for incident acute myeloid leukemia in a Medicare population [0.03%]
医疗保险人口中新诊急性髓系白血病患者实际使用维奈克拉的治疗和利用状况
Joshua A Roth,Paul G D&#x;Amico,Joseph C Cappelleri et al.
Joshua A Roth et al.
Aims: This study aimed to describe first-line venetoclax in the Medicare population and its impacts on treatment patterns, utilization, and costs. Materia...
A multicenter, observational study to evaluate the safety of restarting antitumor therapy recovered from COVID-19 [0.03%]
一项多中心观察性研究：评估新冠肺炎康复后重启抗肿瘤治疗的安全性
Liting Guo,Chenfei Zhou,Wenqi Xi et al.
Liting Guo et al.
Aims: Cancer patients face a higher risk of adverse effects from coronavirus disease 2019 (COVID-19) compared to the general population. However, the safety of restarting antitumor therapy following COVID-19 recovery rema...
A plain language summary of patient preferences for treatments for multiple myeloma that has relapsed or is refractory to prior therapy [0.03%]
关于复发或对既往治疗产生耐药的多发性骨髓瘤患者的治疗偏好的通俗概述
Sikander Ailawadhi,Timothy J Inocencio,Carol Mansfield et al.
Sikander Ailawadhi et al.
A deep learning radiomics model for predicting non-sentinel lymph node metastases in early-stage breast cancer patients [0.03%]
用于预测早期乳腺癌患者非哨淋巴结转移的深度学习影像组学模型
Jiawei Li,Yiyi Miao,Jieying Chen et al.
Jiawei Li et al.
Aims: To develop and validate a deep learning radiomics model to predict non-sentinel lymph node (NSLN) metastases in early-stage breast cancer patients with 1-2 positive sentinel lymph node (SLN) metastases. ...
A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases [0.03%]
关于enzalutamide单药与enzalutamide联合镭[223Th]衰变产物治疗转移性去势抵抗性前列腺癌伴骨转移患者的EORTC 1333/PEACE-3研究的通俗版本摘要
Bertrand Tombal,Fred Saad,Enrique Gallardo et al.
Bertrand Tombal et al.
Long-term safety and effectiveness of ruxolitinib in Japanese patients with polycythemia vera: a post-marketing study [0.03%]
鲁索利替尼治疗日本真性红细胞增多症患者的长期安全性和有效性：一项上市后研究
Tomoko Hayashi,Wataru Hongo,Weizhe Lu
Tomoko Hayashi
Aim: This study evaluated the long-term safety and effectiveness of ruxolitinib in Japanese patients with polycythemia vera in clinical practice. Patients...